Suvir Singh retweeted
Beautiful graph and explanation! Could not help me in invoking AI to transform.
Suvir Singh retweeted
70% of aplastic anemia patients have clonal hematopoiesis, and 15% of them will develop further clonal evolution over the course of their lifetime. If clonal evolution festers, they can go on to develop myeloid malignancies like MDS or AML.
Most clonal hematopoiesis in aplastic anemia is accounted for by genetic mutations in PIGA, DNMT3A, BCOR, and ASXL1, with these clones sometimes preferentially expanding after therapy with immune suppression and eltrombopag. This in turn can lead to myeloid malignancy.
The clonal architecture of aplastic anemia is characterized by early (within 1 year of treatment) or late (after 1 year from treatment) clonal evolution. Early evolution of aplastic anemia into high risk MDS is typically mediated by a chromosome 7 structural aberration, whereas later evolution of aggressive myeloid malignancy usually requires a latency period of at least 2-5 years to manifest.
Late evolution of high risk MDS is characterized by a mutually exclusive ASXL1 or U2AF1 founding mutation. Interestingly, the presence of one of those mutations is not enough to develop high risk MDS. Although ASXL1/U2AF1-mutated clones are detected in 24% aplastic anemia patients at 6 months after treatment with immune suppression and eltrombopag, only 14% of these patients develop high risk MDS. Additional linear evolution with accumulation of a "second hit" mutation like RUNX1 or SETBP1 is necessary for late, high risk MDS transformation.
Aplastic anemia patients can also have concomitant paroxysmal nocturnal hemoglobinuria (PNH). 35% patients with aplastic anemia have PNH clones of at least 1%. Evolution of PNH after aplastic anemia therapy is observed in 5% of patients and is associated with expansion of PIGA mutated clones, often present before treatment. PNH clones greater than 7% is the only predictor for developing clinical PNH after aplastic anemia treatment
@aamdsif
evidence.nejm.org/doi/full/1…
Suvir Singh retweeted
Not all therapies that improve PFS improve OS.
Why?
Because shrinking tumor burden is not always the same as changing tumor biology.
Some therapies reduce disease burden.
Others may reshape immune surveillance itself.
Allogeneic transplant, graft-versus-leukemia effects, and perhaps earlier CAR-T strategies may represent a fundamentally different paradigm.
Not just cytoreduction.
But biologic control.
#AML #MultipleMyeloma #CART #Hemetwitter
PFS is not always OS.
One of the biggest misconceptions in oncology is assuming that delaying progression automatically means patients live longer.
Many strategies consistently improve:
• PFS
• depth of response
• MRD negativity
…but OS often barely moves.
Examples:
• Upfront vs delayed AutoSCT
• Lenalidomide maintenance
• HD melphalan intensification
• Many maintenance strategies in lymphoma
Why?
Because:
• crossover therapies matter
• salvage therapies work
• toxicity matters
• resistant clones survive
• biology evolves
A longer remission is meaningful.
But it is not always a longer life.
The critical question is no longer:
“Did the curve separate?”
The question is:
“What happened to OS?”
#MultipleMyeloma #lymphoma #CART #Hemtwitter
Dr. Fun + G
Suvir Singh retweeted
#COMy2026 #evangelosterpos summarizing one of most practice-changing (even if niche) data I’ve seen for bone-modifying agents in myeloma.
For moderate CKD, consider denosumab 60 mg not 120 mg to lower hypoCa.
Not randomized, but very reasonable given how severe hypoCa can be!
Suvir Singh retweeted
What is cure in cancer?
My talk at the recent IMS cure meeting using myeloma as an example.
Suvir Singh retweeted
With 20 new drug approvals in 20 years, the treatment of relapsed myeloma may appear complex and daunting. Here is a simple way to approach your patient.
In first relapse, you essentially 3 main choices: CART (ciltacel), Tec-Dara, or one of the standard triplets (DPd, DKd, etc).
In second or later relapse, you have an additional key choice, belantamab.
If the patient is not refractory to dara, omit the dara; bispecific alone or non-dara containing triplet (eg KPd).
How to choose?
We usually decide among these 3-4 key options based on patient choice and feasibility. Some patients may prefer the one shot approach with CART. In some, the disease is too aggressive to consider CART. In some, CART or bispecifics may just not be feasible or available and you have to go with triplet or belantamab.
mSMART.org
Suvir Singh retweeted
AI can certainly help with the mundane and clerical tasks. Yes. Thanks.
AI is great at diagnosis. But diagnostic puzzles form a small portion of the care we give or the patients we see. Most of the time the diagnosis is obvious and the main decision is management based on the patients’ unique clinical features, their wishes, goals in life, and analysis of pros and cons based on other comorbidities.
Standard best treatments apply to standard people. But patients are not standard. They are each a unique person and it takes judgment to make the right call on management.
Happy to share our paper on BCR/ABL Negative MPNs:
•Mutational architecture influences survival in Indian MPN patients
•Double-hit mutations confer nearly five-fold higher mortality risk
•JAK2 with high-risk co-mutations defines a poor-risk subgroup
doi.org/10.1016/j.leukres.20…
Suvir Singh retweeted
Replying to @RahulBanerjeeMD @eamadoutoure
Designed for world wide. The high beta 2 applies only if normal renal function. So we wanted to keep it simple. Otherwise the risk Strat will also change by day if creat wobbles around a number. Just make a judgment call whether for the purposes of beta w is the renal function normal.
Suvir Singh retweeted
The website also allows you to calculate the new revised IMS IMWG risk stratification of myeloma.
Just out! New IMS/ IMWG Definition of High Risk Myeloma.
@JCO_ASCO #IMWG25
@Myeloma_Society @IMFmyeloma @NikhilMunshiMD @mvmateos @SagarLonialMD @szusmani @NoopurRajeMD
Happy to share our paper on potential use of dynamic biomarkers (FLC and Creatinine) in identifying a high risk subset of pts with high light chain myeloma.
doi.org/10.1007/s12288-026-0…
Suvir Singh retweeted
This is an incredible progress story
An aggressive type of cancer (Philadelphia chromosome–positive acute lymphoblastic leukemia) used to carry a dismal prognosis, with 50% of patients dying in a year
New therapies have transformed it to a cancer that most people are cured of
Received a challan for ‘jumping’ a red light when the traffic lights were off and some corner lights were blocked by a parked truck.
@LudhianaTraffic @Ludhiana_Police
4
488
Suvir Singh retweeted
🧬 🧵ALL in Adults Over 40 | PI Dr. Punit Jain | #ClinicalTrialsDay
1/
📅 20 May is #ClinicalTrialsDay — a time to recognize how clinical trials transform care and create evidence that saves lives.
Promoted by @ACRPDCsince 2014, it celebrates progress — and the people behind it.
Suvir Singh retweeted
Replying to @rajshekharucms @eClinicalMed
I’ve explained this to Dr. Ludwig in person. That happens because once we make criteria, and publish, practice changes. As a result we only see referrals where the referring physician is not sure whether to treat or not, whereas patients they are more confident get labeled as myeloma and treated and we never see those referrals in academic centers
For example a patient with 110 FLC ratio at a Hb of 14 and creat of 0.7 and normal MRI is referred. But you don’t see anymore the FLC ratio of 200 or 300 with a Hb of 12 because the clinician is more comfortable calling it myeloma and treating.
Or for example an FLC ratio of 110 and BMPC is referred while the FLC ratio of 110 with BMPC of 50% is considered myeloma.
Once we publish criteria the population available to me before the criteria are no longer available. These studies are done with patients diagnosed with slim after the 2014 have a patient population with the top end taken off because those the clinicians don’t have a doubt and you end up seeing the borderline ones. And of course the prog rate in the patients we will be less because it’s a selection bias.
I see this all the time in referrals. Should I treat patients referred are all the borderline 20% Pc with high FLC ratio. Not the 50% with high FLC ratio.
So if take these studies with a grain of salt. It’s important to see if you have a slim cohort diagnosed before 2014 and all consecutive patients seen at an institution(s) to make sure the inception cohort matches ours
Suvir Singh retweeted
Honoured to support the incredible team at DMCH in delivering Punjab’s first CAR-T cell therapy for a patient with relapsed leukemia and CNS involvement.
Huge thanks to Dr. Suvir Singh (@pb10_bmt) for leading the charge and sharing this milestone. From manufacturing to logistics and clinical guidance - grateful to be part of this milestone. Together, we’re pushing boundaries in Indian cancer treatment.
#CARTCellTherapy #ImmunoACT #CancerTreatment #MadeInIndia #BreakthroughTherapy
🌟 Proud Moment! 🌟
We performed the first CAR-T cell therapy in Punjab and the northern Indian region for a patient with refractory B-ALL. This makes us one of the first few institutions in India to offer this level of treatment. @ActImmuno
Suvir Singh retweeted
🧠 AML in Older Adults | Dr. Suvir Singh |
🧵1/
📅 20 May marks #ClinicalTrialsDay, promoted by @ACRPDC since 2014 to celebrate the people, science, and impact behind clinical research.
Today, we spotlight a powerful study on AML in older Indian adults, led by Dr. @pb10_bmt































